The EPS projection of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) for quarter ended 2016-09-30 is $0.16. A week before, the EPS forecast was $0.16 against target of $0.16, a month earlier. This estimate stood at $0.16 60 days earlier versus forecast of $0.16 90 days earlier, confirming a deviation of 0.02%.
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) reported that 18 days ago, the positive EPS revisions were 2 and negative revisions at 1.
In last week, the per-share earnings was lowered 0 times and 1 times positively. In last 120, 60, 30 and 90 days the positive revisions were 3, 3, 1 and 3, respectively.
The downgrade of EPS estimates for Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) in the preceding 120, 60, 30 and 90 days were 1, 1, 0 and 1, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) was $0.16. This projection was computed after accounting 5 calls. As reported on 2016-05-03 the EPS was $0.02. The change was $0, demonstrating a percentage deviation of 0%. The projections confirmed a standard deviation of 0.04.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) stands at $103.056 and the median estimate at $101.7. Almost 3 analysts announced their estimates.
The highest estimate is $110.47 while the lowest target is $97 showing standard deviation of 6.836%.
As many as 3 analysts released sales estimates reised in upside while 3 reduced sales estimates, demonstrating a deviation of 2.316%.
In last month, 3 revised sales number projection on upside while 3 lowered the sales target, demonstrating a deviation of 2.316%.
A quarter ago, 3 hiked sales estimations and 3 reduced sales forecast. Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) stated that the change in forecast was 3.449%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...